13 studies found for:    voreloxin | Exclude Unknown
Show Display Options
Rank Status Study
1 Completed Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Condition: Acute Myeloid Leukemia
Intervention: Drug: voreloxin injection and cytarabine
2 Completed Study of Voreloxin in Older Patients With Untreated Acute Myeloid Leukemia
Conditions: Leukemia;   Acute Disease;   Acute Myeloid Leukemia;   Nonlymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: voreloxin
3 Recruiting Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: vosaroxin;   Drug: Azacitidine
4 Recruiting Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
Condition: Myelodysplastic Syndrome
Intervention: Drug: Vosaroxin
5 Completed Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention: Drug: Voreloxin Injection
6 Active, not recruiting Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)
Conditions: Leukemia;   Acute Myeloid Leukemia;   Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine;   Drug: placebo and cytarabine
7 Recruiting Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Condition: Leukemia
Interventions: Drug: Vosaroxin;   Drug: Decitabine
8 Not yet recruiting Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Vosaroxin and Cytarabine
9 Completed Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
Conditions: Leukemia, Lymphocytic, Acute;   Leukemia, Nonlymphocytic, Acute;   Leukemia, Myeloid, Chronic;   Myelodysplastic Syndromes
Intervention: Drug: SNS-595 Injection
10 Completed Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
Condition: Neoplasms
Intervention: Drug: SNS-595
11 Completed Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
Condition: Neoplasms
Intervention: Drug: SNS-595
12 Completed Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Conditions: Carcinoma, Small Cell;   Small Cell Lung Cancer
Intervention: Drug: SNS-595 Injection
13 Completed Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: SNS-595 Injection

Indicates status has not been verified in more than two years